<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459939</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1604</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101604</ELocationID><Abstract><AbstractText>The ISARIC 4C Mortality score was developed to predict mortality risk among patients with COVID-19. Its performance among vaccinated individuals is understudied. This is a retrospective study of all patients with SARS-CoV-2 infection admitted to the National Centre for Infectious Diseases, Singapore, from January-2020 to December-2021. Demographic, clinical, and laboratory data were extracted, and multiple logistic regression (MLR) models were developed to predict the relationship between ISARIC score, vaccination status, anti-S antibody titre, and severe COVID-19. A total of 6377 patients were identified, of which 5329 met the study eligibility criteria. The median age of the patients was 47 years (IQR 35-71), 1264 (23.7%) were female, and 1239 (25.7%) were vaccinated. Severe disease occurred in 499 (9.4%) patients, including 133 (2.5%) deaths. After stratification, 3.0% of patients with low (0-4), 17.8% of patients with moderate (5-9), and 36.2% of patients with high (≥10) ISARIC scores developed severe COVID-19. Vaccination was associated with a reduced risk of progression to severe COVID-19 in the MLR model: aOR 0.88 (95% CI: 0.86-0.90), and the risk of severe COVID-19 decreased inversely to anti-S antibody titres. The anti-S antibody titre should be further investigated as an adjunct to the ISARIC score to triage COVID-19 patients for hospital admission and antiviral therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Lin Pin</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Travis Ren Teen</ForeName><Initials>TRT</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Samuel Sherng Young</ForeName><Initials>SSY</Initials><Identifier Source="ORCID">0000-0002-1013-7364</Identifier><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavatte</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-0003-541X</Identifier><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ting</LastName><ForeName>Yonghan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8682-9914</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim</LastName><ForeName>Jordan Zheng Ting</ForeName><Initials>JZT</Initials><Identifier Source="ORCID">0000-0002-4164-1643</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen Xiang</ForeName><Initials>WX</Initials><AffiliationInfo><Affiliation>Department of Radiology, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Kelvin Bryan</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Ministry of Health, 16 College Road, College of Medicine Building, Singapore 169854, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Cher Heng</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lye</LastName><ForeName>David Chien</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-0324-0205</Identifier><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Barnaby E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>National Centre for Infectious Diseases, Singapore 308442, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore 308433, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COVID19RF-008</GrantID><Agency>Singapore National Medical Research Council</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012846" MajorTopicYN="N" Type="Geographic">Singapore</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ISARIC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">modelling</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>BEY reported personal fees from AstraZeneca, Gilead, Moderna, Sanofi, and Pfizer outside the submitted work. All other authors declared no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459939</ArticleId><ArticleId IdType="pmc">PMC11512353</ArticleId><ArticleId IdType="doi">10.3390/v16101604</ArticleId><ArticleId IdType="pii">v16101604</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riou J., Althaus C.L. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Eurosurveillance. 2020;25:2000058. doi: 10.2807/1560-7917.ES.2020.25.4.2000058.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.4.2000058</ArticleId><ArticleId IdType="pmc">PMC7001239</ArticleId><ArticleId IdType="pubmed">32019669</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber R.M., Sorensen R.J.D., Pigott D.M., Bisignano C., Carter A., Amlag J.O., Collins J.K., Abbafati C., Adolph C., Allorant A., et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: A statistical analysis. Lancet. 2022;399:2351–2380. doi: 10.1016/S0140-6736(22)00484-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00484-6</ArticleId><ArticleId IdType="pmc">PMC8993157</ArticleId><ArticleId IdType="pubmed">35405084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., et al. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399:1513–1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S., Kim L., Whitaker M., O’Halloran A., Cummings C., Holstein R., Prill M., Chai S.J., Kirley P.D., Alden N.B., et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. Morb. Mortal. Wkly. Rep. 2020;69:458–464. doi: 10.15585/mmwr.mm6915e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6915e3</ArticleId><ArticleId IdType="pmc">PMC7755063</ArticleId><ArticleId IdType="pubmed">32298251</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S.W.X., Tham S.M., Koh L.P., Dugan C., Khoo B.Y., Ren D., Sutjipto S., Lee P.H., Young B.E., Lye D.C. External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients. Clin. Microbiol. Infect. 2022;28:884.e1–884.e3. doi: 10.1016/j.cmi.2022.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.031</ArticleId><ArticleId IdType="pmc">PMC8828384</ArticleId><ArticleId IdType="pubmed">35150879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R.K., Harrison E.M., Ho A., Docherty A.B., Knight S.R., van Smeden M., Abubakar I., Lipman M., Quartagno M., Pius R., et al. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: A prospective cohort study. Lancet Respir. Med. 2021;9:349–359. doi: 10.1016/S2213-2600(20)30559-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30559-2</ArticleId><ArticleId IdType="pmc">PMC7832571</ArticleId><ArticleId IdType="pubmed">33444539</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight S.R., Ho A., Pius R., Buchan I., Carson G., Drake T.M., Dunning J., Fairfield C.J., Gamble C., Green C.A., et al. Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339. doi: 10.1136/bmj.m3339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3339</ArticleId><ArticleId IdType="pmc">PMC7116472</ArticleId><ArticleId IdType="pubmed">32907855</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim J.Z.T., Ting Y.-H., Tang Y., Feng Y., Lei X., Wang X., Chen W.-X., Huang S., Wong S.-T., Lu Z., et al. Diagnostic Performance of a Deep Learning Model Deployed at a National COVID-19 Screening Facility for Detection of Pneumonia on Frontal Chest Radiographs. Healthcare. 2022;10:175. doi: 10.3390/healthcare10010175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10010175</ArticleId><ArticleId IdType="pmc">PMC8775598</ArticleId><ArticleId IdType="pubmed">35052339</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A., Lee Y., Roosa K., Blumberg S., Yan P., Ma S., Chowell G. Real-time monitoring the transmission potential of COVID-19 in Singapore, March 2020. BMC Med. 2020;18:166. doi: 10.1186/s12916-020-01615-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01615-9</ArticleId><ArticleId IdType="pmc">PMC7268586</ArticleId><ArticleId IdType="pubmed">32493466</ArticleId></ArticleIdList></Reference><Reference><Citation>MOH|News Highlights.  [(accessed on 17 March 2023)]; Available online:  https://www.moh.gov.sg/news-highlights/details/preparing-for-our-transition-towards-covid-resilience.</Citation></Reference><Reference><Citation>MOH|News Highlights.  [(accessed on 17 March 2023)]; Available online:  https://www.moh.gov.sg/news-highlights/details/data-on-persons-testing-positive-with-covid-19-serving-quarantine-orders-at-home-and-medical-treatment-provided-to-them/</Citation></Reference><Reference><Citation>Premikha M., Chiew C.J., Wei W.E., Leo Y.S., Ong B., Lye D.C., Lee V.J., Tan K.B. Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore. Clin. Infect. Dis. 2022;75:1442–1445. doi: 10.1093/cid/ciac288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac288</ArticleId><ArticleId IdType="pmc">PMC9047219</ArticleId><ArticleId IdType="pubmed">35412612</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Coyle P., Malek J.A., Ahmed A.A., Mohamoud Y.A., Younuskunju S., Ayoub H.H., Al Kanaani Z., Al Kuwari E., et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. eClinicalMedicine. 2021;35:100861. doi: 10.1016/j.eclinm.2021.100861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100861</ArticleId><ArticleId IdType="pmc">PMC8079668</ArticleId><ArticleId IdType="pubmed">33937733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S.W.X., Sutjipto S., Lee P.H., Dugan C., Khoo B.Y., Ren D., Young B.E., Lye D.C. Validation of ISARIC 4C Mortality and Deterioration Scores in a Mixed Vaccination Status Cohort of Hospitalized Coronavirus Disease 2019 (COVID-19) Patients in Singapore. Clin. Infect. Dis. 2022;75:e874–e877. doi: 10.1093/cid/ciac087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac087</ArticleId><ArticleId IdType="pmc">PMC8903389</ArticleId><ArticleId IdType="pubmed">35134143</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiteri G., D’Agostini M., Abedini M., Ditano G., Collatuzzo G., Boffetta P., Vimercati L., Sansone E., De Palma G., Modenese A., et al. Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project. Infection. 2024;52:1347–1356. doi: 10.1007/s15010-024-02189-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-024-02189-x</ArticleId><ArticleId IdType="pmc">PMC11289150</ArticleId><ArticleId IdType="pubmed">38326526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia T.R.T., Young B.E., Chia P.Y. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann. Acad. Med. 2022;51:712–729. doi: 10.47102/annals-acadmedsg.2022294.</Citation><ArticleIdList><ArticleId IdType="doi">10.47102/annals-acadmedsg.2022294</ArticleId><ArticleId IdType="pubmed">36453218</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeller M.E., Engsig F.N., Bade M., Fock J., Pah P., Soerensen A.L., Bang D., Donolato M., Benfield T. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. Microbiol. Spectr. 2022;10:e00396-22. doi: 10.1128/spectrum.00396-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00396-22</ArticleId><ArticleId IdType="pmc">PMC9045215</ArticleId><ArticleId IdType="pubmed">35357223</ArticleId></ArticleIdList></Reference><Reference><Citation>Low E.V., Teh H.S., Hing N.Y.L., Chidambaram S.K., Pathmanathan M.D., Kim W.R., Lee W.J., Teh Z.W., Appannan M.R., Zin S.M., et al. Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective. Drugs-Real World Outcomes. 2024;11:299–308. doi: 10.1007/s40801-024-00427-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40801-024-00427-0</ArticleId><ArticleId IdType="pmc">PMC11176137</ArticleId><ArticleId IdType="pubmed">38727886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Li L., Zhou Z., Liu Q., Wang G., Liu D. Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China. Front. Public Health. 2023;11:1174879. doi: 10.3389/fpubh.2023.1174879.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1174879</ArticleId><ArticleId IdType="pmc">PMC10315619</ArticleId><ArticleId IdType="pubmed">37404282</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S., Champion J., Moultrie H., Bekker L.-G., Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N. Engl. J. Med. 2022;386:494–496. doi: 10.1056/NEJMc2119270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119270</ArticleId><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>